Voyager Therapeutics, Inc. VYGR

- Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented six-month good laboratory practice (GLP) toxicology data for VY1706, the Company’s investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease (AD), in a Developing Topics (late-breaking) poster presen

Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London.

On the June 30 episode of Mad Money, a 23-year-old caller named Jackson from Iowa asked Jim Cramer about Voyager Therapeutics (NASDAQ:VYGR), a clinical-stage gene therapy company he wanted to hold for the long haul. Cramer’s response was a shrug wrapped around a birthday card. “Only because you told me that can I encourage you ... Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money

Voyager Therapeutics Inc. (NASDAQ:VYGR) is one of the 10 best stocks under $10 offering more than 50% upside. Back on June 1, Voyager Therapeutics Inc. (NASDAQ:VYGR) received FDA approval for VY1706, a gene therapy for Alzheimer’s that targets extracellular and intracellular tau. The company had previously submitted an Investigational New Drug (IND) application, and this […]

LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) poster presentation at the upcoming Alzheimer's Association International Conference (AAIC) taking place in London, July 12-15, 2026. The Developing Topics poster presentation will feature VY1706, Voyager’s investigational gene therapy targeting intracellular and

LEXINGTON, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, will participate in a pre-recorded fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. An on-demand webcast of the pre-recorded fireside chat will be available and may be accessed from th

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

- Dosing of adults with early Alzheimer’s disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 - - VY1706 uses an IV-delivered, brain-targeted capsid to reduce intracellular and extracellular tau - LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the U.S.

Voyager Therapeutics Inc (NASDAQ:VYGR) is one of the best gene therapy stocks to buy in 2026. While the stock has risen only a modest 30% over the past year, analysts believe it can explode more than 250% over the next 12 months as the company advances its drug programs. On May 13, Voyager Therapeutics announced […]

- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager’s continued innovation in gene therapy - LEXINGTON, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented three-month good laboratory practice (GLP) toxicology data for VY1706, the Company’s investigational tau silencing

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of +12.96% and -74.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month GLP tox data - - Ended Q1 2026 with cash position of $172 million, runway into 2028 - LEXINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported first quarter 2026 financial and operat

- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs - - Additional data demonstrate continued capsid innovation via muscular and neuromuscular targeting, immune evasion, and manufacturability - LEXINGTON, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurolo

Voyager Therapeutics, Inc. reported fourth-quarter 2025 results showing a net loss of US$27.43 million versus US$34.49 million a year earlier, while its full-year 2025 net loss widened to US$119.72 million from US$65.00 million. Although the quarterly loss per share from continuing operations narrowed to US$0.47 basic (US$0.46 diluted), the full-year loss per share increased to US$2.04 basic and diluted, underscoring the cost of advancing its neurology-focused pipeline. We’ll now examine how...